MEDS VS NVS Stock Comparison
Performance
MEDS10/100
10/100
MEDS returned -41.09% in the last 12 months. Based on SPY's performance of -13.95%, its performance is below average giving it a score of 10 of 100.
NVS100/100
100/100
NVS returned 11.56% in the last 12 months. Based on SPY's performance of -13.77%, its performance is above average giving it a score of 100 of 100.
Technicals
MEDS36/100
36/100
MEDS receives a 35 of 100 based on 14 indicators. 4 are bullish, 8 are bearish.
NVS10/100
10/100
NVS receives a 10 of 100 based on 14 indicators. 0 are bullish, 12 are bearish.
Earnings
MEDS10/100
10/100
MEDS has missed earnings 9 times in the last 20 quarters.
NVS39/100
39/100
NVS has missed earnings 5 times in the last 20 quarters.
Profit
MEDS22/100
22/100
Out of the last 20 quarters, MEDS has had 6 profitable quarters and has increased their profits year over year on 2 of them.
NVS73/100
73/100
Out of the last 20 quarters, NVS has had 20 profitable quarters and has increased their profits year over year on 8 of them.
Volatility
MEDS52/100
52/100
MEDS has had a higher than average amount of volatility over the last 12 months giving it a score of 52 of 100.
NVS44/100
44/100
NVS has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.
Analyst Price Targets
MEDS
"Analyst Price Targets" not found for MEDS
NVS67/100
67/100
3 analysts offer 12-month price targets for NVS. Together, they have an average target of 0, the most optimistic target put NVS at 0 within 12-months and the most pessimistic has NVS at 0.
All score calculations are broken down here to help you make more informed investing decisions
TRxADE HEALTH, Inc. Common Stock Summary
Nasdaq / MEDS
Healthcare
Medical - Pharmaceuticals
TRxADE HEALTH, Inc. operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. It operates the TRxADE drug procurement marketplace, which fosters price transparency and serves approximately 11,800 members; and offers patient centric telehealth services under the Bonum Health brand name. The company was formerly known as Trxade Group, Inc. and changed its name to TRxADE HEALTH, Inc. in June 2021. TRxADE HEALTH, Inc. is based in Land O' Lakes, Florida.
Novartis AG Summary
New York Stock Exchange / NVS
Healthcare
Drug Manufacturers - General
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Power up your portfolio
Build a portfolio of your favorite stocks
Pluto makes it easy to build investing strategies and automate your portfolio
Compare Similar Companies
Compare MEDS to other companies in the same or a similar industry.